Investor Relations
Sep 14, 2018
OPKO Confirms Resumption of Common Stock Trading on Nasdaq MORE >>
Sep 11, 2018
OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock MORE >>
Sep 07, 2018
OPKO Comments on SEC Complaint MORE >>
Sep 04, 2018
OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients MORE >>

Press Releases

All Releases
OPKO Announces Fourth Quarter Operating and Financial Results
Feb 27, 2015
Pfizer Collaboration Agreement for Long Acting Human Growth Hormone Closed in January 2015 ; OPKO Received $295 Million of $570 Million Total Potential Up Front and Milestone Payments Rayaldee TM New Drug Application (NDA) Submission Planned for Q1 2015 Positive Rayaldee Phase 3 Clinical Trial
OPKO to Announce Fourth Quarter and Full Year 2014 Financial Results on February 27, 2015
Feb 26, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) will announce fourth quarter and full year 2014 financial results on Friday, February 27 , after the close of the U.S. financial markets. OPKO's senior management will host a conference call and live audio webcast to provide a business update
OPKO Announces Publication of 20 Year Outcome Study for Lethal Prostate Cancer Using Kallikrein Biomarkers in 4Kscore Test
Feb 20, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled "Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study" in the journal
OPKO Health to Present at the 2015 RBC Capital Markets' Healthcare Conference
Feb 13, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the 2015 RBC Capital Markets' Healthcare Conference on Wednesday, February 25, 2015 at 2:35 PM (ET) . OPKO's senior management will provide a review of recent corporate developments.
OPKO Submits Investigational New Drug Application to Initiate a Phase 2a Trial for its Long-Acting Coagulation Factor VIIa-CTP to Treat Hemophilia
Jan 30, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health , Inc. (NYSE:OPK) announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to conduct a Phase 2a study of OPKO's long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for the treatment
OPKO and Pfizer Receive Regulatory Clearance for Global Agreement
Jan 29, 2015
MIAMI & NEW YORK --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE: PFE) today announced the closing of their worldwide agreement for the development and commercialization of hGH-CTP, a long-acting human growth hormone. The closing follows termination of the waiting period
OPKO Launches the 4Kscore Test in Mexico
Jan 28, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the launch of the 4Kscore® test, the only blood test that accurately identifies risk for aggressive prostate cancer, in Mexico through its wholly owned subsidiary, OPKO Health Mexico. The launch in Mexico follows the U.S.
OPKO Claros1 Analyzer Selected for Development of a Rapid Lyme Disease Test Under Immuno Technologies NIH Grant
Jan 13, 2015
MIAMI & MEMPHIS, Tenn. --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) and Immuno Technologies, Inc. today announced that the National Institutes of Health (NIH) has awarded a $3 million grant to develop a rapid diagnostic test for Lyme disease. The Phase II Small Business Innovation Research
OPKO Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Jan 05, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that senior management will present at the 33 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 4:00 PM PT . A live audio webcast of the presentation will be accessible through the OPKO Investor
OPKO and Pfizer Enter into Global Agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP)
Dec 15, 2014
  • hGH-CTP in global clinical development for the treatment of pediatric and adult growth hormone deficiency (GHD)
  • hGH-CTP has potential to reduce dosing frequency of human growth hormone to single weekly injection from current standard of daily injection
  • OPKO to receive upfront payment of $295 million and eligible to receive up to an additional $275 million upon achievement of regulatory milestones
  • Upon Pfizer's commercialization of hGH-CTP, OPKO is eligible to receive royalty and/or profit sharing payments
  • Pfizer to obtain exclusive license to commercialize hGH-CTP globally
OPKO Health to Present at the Oppenheimer 25th Annual Healthcare Conference
Dec 03, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Oppenheimer 25 th Annual Healthcare Conference on Wednesday, December 10, 2014 at 10:20 AM (ET) . OPKO's senior management will provide a review of recent corporate developments.
OPKO Health to Present at the Jefferies 2014 Global Healthcare Conference
Nov 13, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, November 19, 2014 at 4:20 PM GMT in London . About OPKO Health, Inc. OPKO is a multi-national biopharmaceutical and diagnostics
OPKO Announces Publication of Large, Prospective, Multi-Institutional Clinical Validation of the 4Kscore™ Test for High Grade Prostate Cancer in the United States
Nov 10, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a multi-institutional, prospective study of the 4Kscore Test in the journal European Urology . The results of the study demonstrated that the 4Kscore provides a patient with accurate and personalized
OPKO To Hold Conference Call on November 10, 2014
Nov 07, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) will hold a conference call to provide a business update and discuss its third quarter 2014 financial results on Monday, November 10, 2014 , before the market opens. OPKO's senior management team will host a conference call and live audio
OPKO Announces Third Quarter Operating and Financial Results
Nov 07, 2014
Rayaldee™ Meets Primary Endpoints in Both Pivotal Phase 3 Trials; NDA Submission Planned for Q4 2014 Rayaldee Results to be Presented at American Society of Nephrologists Meeting Clinical Trial Start for Rayaldee as Adjunctive Cancer Therapy to Begin in Q4 2014 European Marketing Commenced for
Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A Multinational, Multicenter Early Feasibility Trial of the TiaraTM Transcatheter Mitral Valve
Oct 09, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) announced that its investee, Neovasc, has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's
OPKO Health Supports National Prostate Cancer Council Legislation
Sep 29, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) is pleased to lend its support to the legislation introduced in the United States Senate on September 16, 2014 by Senators Jeff Sessions (R-AL) and Barbara Boxer (D-CA) legislating the formation of the National Prostate Cancer Council (NPCC).
OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints
Sep 23, 2014
Targeted Response Rate Achieved for Plasma Parathyroid Hormone Reduction Favorable Adverse Event Profile Consistent with First Phase 3 Trial New Drug Application Submission to U.S. FDA Planned for End of 2014 MIAMI --(BUSINESS WIRE)-- OPKO Health , Inc. (NYSE: OPK), announced successful top-line
OPKO Launches the 4Kscore Test in Europe
Sep 15, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the European launch of the 4Kscore ™ Test, the only blood test that accurately identifies risk for aggressive prostate cancer, through its wholly owned subsidiary, OPKO Health Spain. The launch in Europe follows the U.S.
Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference
Sep 11, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced that the abstract "Top Line Results of Once-Weekly , CTP-Modified Human Growth Hormone (MOD-4023): Phase 2 Dose Finding Study in Children with Growth Hormone Deficiency (GHD)" has been selected for late breaking oral
Displaying 161 - 180 of 363